[go: up one dir, main page]

NL301332I2 - garadacimab - Google Patents

garadacimab

Info

Publication number
NL301332I2
NL301332I2 NL301332C NL301332C NL301332I2 NL 301332 I2 NL301332 I2 NL 301332I2 NL 301332 C NL301332 C NL 301332C NL 301332 C NL301332 C NL 301332C NL 301332 I2 NL301332 I2 NL 301332I2
Authority
NL
Netherlands
Prior art keywords
garadacimab
Prior art date
Application number
NL301332C
Other languages
English (en)
Dutch (nl)
Original Assignee
Csl Ltd
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11175105A external-priority patent/EP2548892A1/fr
Application filed by Csl Ltd, Csl Behring Gmbh filed Critical Csl Ltd
Publication of NL301332I2 publication Critical patent/NL301332I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
NL301332C 2011-07-22 2025-06-17 garadacimab NL301332I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161510801P 2011-07-22 2011-07-22
EP11175105A EP2548892A1 (fr) 2011-07-22 2011-07-22 Anticorps inhibiteurs monoclonal contre Factor XII/XIIa et leurs utilisations
EP12153310 2012-01-31
PCT/EP2012/064322 WO2013014092A1 (fr) 2011-07-22 2012-07-20 Anticorps monoclonaux inhibiteurs anti-facteur xii/xiia et leurs utilisations
EP12735916.4A EP2734552B1 (fr) 2011-07-22 2012-07-20 Anticorps inhibiteurs monoclonal contre factor xii/xiia et leurs utilisations

Publications (1)

Publication Number Publication Date
NL301332I2 true NL301332I2 (nl) 2025-09-10

Family

ID=47600530

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301332C NL301332I2 (nl) 2011-07-22 2025-06-17 garadacimab

Country Status (26)

Country Link
US (5) US9518127B2 (fr)
EP (2) EP4516811A3 (fr)
JP (1) JP6253578B2 (fr)
KR (1) KR102042982B1 (fr)
CN (1) CN103687878B (fr)
AU (1) AU2012289001B2 (fr)
BR (1) BR112014001104B1 (fr)
CA (1) CA2841185C (fr)
DK (1) DK2734552T3 (fr)
ES (1) ES3005912T3 (fr)
FI (2) FI2734552T3 (fr)
FR (1) FR25C1026I1 (fr)
HR (1) HRP20250164T1 (fr)
HU (2) HUE070002T2 (fr)
IL (2) IL230564B2 (fr)
LT (2) LT2734552T (fr)
MX (1) MX347454B (fr)
NL (1) NL301332I2 (fr)
NO (1) NO2025031I1 (fr)
PL (1) PL2734552T3 (fr)
PT (1) PT2734552T (fr)
RS (1) RS66465B1 (fr)
RU (1) RU2660370C2 (fr)
SI (1) SI2734552T1 (fr)
SM (1) SMT202500041T1 (fr)
WO (1) WO2013014092A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66465B1 (sr) * 2011-07-22 2025-02-28 Csl Behring Gmbh Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
EP2623110A1 (fr) * 2012-01-31 2013-08-07 CSL Behring GmbH Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
PL3013366T3 (pl) * 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
EP3240570B1 (fr) * 2015-01-02 2025-09-24 Takeda Pharmaceutical Company Limited Anticorps bispécifiques agissant à l'encontre la kallicréine plasmatique et du facteur xii
EA201890340A1 (ru) * 2015-07-21 2018-09-28 Дайэкс Корп. Моноклональное антитело-ингибитор фактора xiia
AR107505A1 (es) * 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
KR20230136687A (ko) * 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법
EP3493832A1 (fr) 2016-08-05 2019-06-12 CSL Behring GmbH Formulations pharmaceutiques de l'inhibiteur d'estérase c1
WO2019030706A1 (fr) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv Molécules d'anticorps anti-thrombine et méthodes d'utilisation en chirurgie orthopédique
WO2019035055A1 (fr) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv Molécules d'anticorps anti-thrombine et procédés d'utilisation avec des agents antiagrégants plaquettaires
BR112020011240A2 (pt) * 2017-12-15 2020-11-24 Csl Limited uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica
EA202190056A1 (ru) * 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
WO2020113084A1 (fr) * 2018-11-28 2020-06-04 Oregon Health & Science University Anticorps anti-facteur xii thérapeutique
WO2020248024A1 (fr) * 2019-06-12 2020-12-17 CSL Innovation Pty Ltd Conjugués de variant de type 1 du récepteur de complément soluble et utilisations associées
CA3159675A1 (fr) * 2019-12-03 2021-06-10 Ingo Pragst Utilisation d'un anticorps anti-facteur xii pour le traitement ou la prevention de l'oedeme de quincke hereditaire
WO2021253662A1 (fr) * 2020-06-16 2021-12-23 宁波康善生物科技有限公司 Nanocorps anti-fxii ou fragment de liaison à l'antigène de celui-ci et son utilisation
CA3183508A1 (fr) * 2020-07-03 2022-01-06 Michael Johnston Formulation a haute concentration de proteines de liaison a l'antigene du facteur xii
CN116265945B (zh) * 2022-01-05 2025-12-09 上海迈晋生物医药科技有限公司 抗凝血药物的生物学活性检测方法
WO2024255794A1 (fr) * 2023-06-16 2024-12-19 舒泰神（北京）生物制药股份有限公司 Anticorps reconnaissant de manière spécifique le facteur xiia et son utilisation
WO2025019789A1 (fr) 2023-07-19 2025-01-23 Regeneron Pharmaceuticals, Inc. Anticorps anti-facteur xii/xiia et leurs utilisations

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
EP0401384B1 (fr) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901859D0 (en) * 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (fr) * 1990-05-10 1993-04-07 Cetus Corporation Inhibiteurs de l'activation du facteur xii et leurs applications
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
EP1621206A1 (fr) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Cytokines chimeres et leur utilisation
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
CA2405550A1 (fr) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Proteines fusionnees a de l'albumine
US20040077538A1 (en) 2000-05-17 2004-04-22 Harvey Pollard Use of factor XIIa for treatment of hemophilia A and B and prevention of bleeding
EP2275449B1 (fr) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Anticorps se liant de manière immunospécifique à un stimulateur de lymphocyte B (BLyS)
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2003076567A2 (fr) 2002-03-05 2003-09-18 Eli Lilly And Company Proteines hybrides g-csf heterologues
AU2003290689A1 (en) * 2002-11-08 2004-06-03 Kyowa Hakko Kirin Co., Ltd. Transgenic ungulates having reduced prion protein activity and uses thereof
GB0229837D0 (en) * 2002-12-20 2003-01-29 Axis Shield Diagnostics Ltd Variants of activated factor XII
BR0317404A (pt) * 2002-12-20 2005-11-16 Axis Shield Diagnostics Ltd Variantes do fator xiia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
CA2528591C (fr) 2003-06-12 2013-01-08 Eli Lilly And Company Proteines hybrides analogues de glp-1
AU2004266246A1 (en) * 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
EP1598428A1 (fr) * 2004-05-18 2005-11-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
WO2006017538A2 (fr) * 2004-08-03 2006-02-16 Dyax Corp. Proteines de liaison a la proteine hk1
EP1810979B1 (fr) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. ANTICORPS IgG4 HUMAINS STABILISES
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005318464B2 (en) * 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
EP3028716B1 (fr) 2006-10-10 2020-09-16 Regenesance B.V. Inhibition du complément pour régénération nerveuse améliorée
JP2010518039A (ja) 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
AU2009221915A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
KR20110089185A (ko) * 2008-11-25 2011-08-04 바이오겐 아이덱 엠에이 인코포레이티드 신경계 세포의 생존을 촉진하기 위한 ｄｒ６ 및 ｐ７５ 길항제의 용도
CN102369021B (zh) 2008-12-19 2016-09-07 宏观基因有限公司 共价双抗体及其用途
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
ES2905545T3 (es) * 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2371857A1 (fr) * 2010-04-01 2011-10-05 CSL Behring GmbH Inhibiteurs de facteur XII pour traiter la maladie de poumon interstitiel
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
RS66465B1 (sr) * 2011-07-22 2025-02-28 Csl Behring Gmbh Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe

Also Published As

Publication number Publication date
SI2734552T1 (sl) 2025-03-31
AU2012289001B2 (en) 2016-03-03
IL230564B2 (en) 2023-09-01
HUS2500028I1 (hu) 2025-07-28
IL291613A (en) 2022-05-01
ES3005912T3 (en) 2025-03-17
EP4516811A2 (fr) 2025-03-05
KR102042982B1 (ko) 2019-11-11
EP2734552B1 (fr) 2024-11-13
US20180134806A1 (en) 2018-05-17
AU2012289001A1 (en) 2013-05-02
US20170121423A1 (en) 2017-05-04
HRP20250164T1 (hr) 2025-04-11
CN103687878A (zh) 2014-03-26
RU2660370C2 (ru) 2018-07-05
IL230564B1 (en) 2023-05-01
HUE070002T2 (hu) 2025-04-28
US11345759B2 (en) 2022-05-31
BR112014001104A2 (pt) 2017-12-12
US9856326B2 (en) 2018-01-02
MX2014000363A (es) 2014-03-27
PT2734552T (pt) 2025-01-29
SMT202500041T1 (it) 2025-03-12
US10513560B2 (en) 2019-12-24
CN103687878B (zh) 2018-01-09
MX347454B (es) 2017-04-27
US9856325B2 (en) 2018-01-02
FR25C1026I1 (fr) 2025-09-19
KR20140054112A (ko) 2014-05-08
RS66465B1 (sr) 2025-02-28
IL291613B1 (en) 2025-08-01
WO2013014092A1 (fr) 2013-01-31
BR112014001104B1 (pt) 2022-12-06
NO2025031I1 (no) 2025-07-09
IL291613B2 (en) 2025-12-01
EP4516811A3 (fr) 2025-03-26
IL230564A0 (en) 2014-03-31
DK2734552T3 (da) 2024-12-09
US20140199361A1 (en) 2014-07-17
LTPA2025524I1 (fr) 2025-07-10
JP6253578B2 (ja) 2017-12-27
NZ619385A (en) 2016-07-29
CA2841185C (fr) 2021-05-25
EP2734552A1 (fr) 2014-05-28
US9518127B2 (en) 2016-12-13
RU2014106652A (ru) 2015-08-27
US20200062863A1 (en) 2020-02-27
FI2734552T3 (fi) 2025-02-12
US20170137536A1 (en) 2017-05-18
LT2734552T (lt) 2025-01-10
PL2734552T3 (pl) 2025-03-24
CA2841185A1 (fr) 2013-01-31
HK1198334A1 (en) 2015-04-02
FIC20250024I1 (fi) 2025-07-08
JP2014523253A (ja) 2014-09-11

Similar Documents

Publication Publication Date Title
NL301332I2 (nl) garadacimab
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2780065A4 (fr) Système de masque nasal
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
EP2752374A4 (fr) Récipient-verseur
EP2795884A4 (fr) Audioconférence
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
EP2701512A4 (fr) Inhibiteurs d'aldostérone synthase
EP2768739A4 (fr) Contenant à fluide de lavage oculaire
EP2786752A4 (fr) Timbre adhésif contenant du ropinirole
EP2723481A4 (fr) Compensateur de flux
DK3141251T3 (da) Koloskopi - forberedelse
EP2708561A4 (fr) Bio-aiguille
EP2762923A4 (fr) Radiamètre
EP2738148A4 (fr) Bloc à verrouillage réciproque
DE112011104936A5 (de) Stanzstauchniet
EP2760803A4 (fr) Produit en géopolymère
EP2771685A4 (fr) Biomarqueurs du cancer
DE112012000958A5 (de) Handsäge
EP2788163A4 (fr) Système de post-moulage
EP2729467A4 (fr) Composés cryptates
EP2698098A4 (fr) Campimètre
DK2476953T3 (da) Fluidbedkedel